76.04 NTLA Candlestick Chart & Stock Ticker

StockScan › Stocks › NTLA

NTLA

76.04

0.60% -0.46

(After Hours: 75.92 -0.1200 -0.16%)

Intellia Therapeutics

News Options Financials Holders Transactions Discussions Predictions

Jun-14-21 10:50AM	CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 DataZacks Investment Research
Jun-13-21 05:11AM	3 Biotech ETFs That Could Double Your Money by 2025 With Zero EffortThe Motley Fool
Jun-11-21 11:31AM	Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021Benzinga
Jun-07-21 07:11AM	What's the Best Way to Invest in Genetics Stocks?The Motley Fool
Jun-03-21 07:39AM	This Genetics Stock Could Have a Bright FutureThe Motley Fool
May-26-21 06:05AM	4 Unstoppable Healthcare Stocks to Buy on the DipThe Motley Fool
May-17-21 06:15AM	Earnings Roundup: General Motors, Editas Medicine, Activision Blizzard, Match GroupThe Motley Fool
May-07-21 06:00AM	Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call TranscriptMotley Fool
May-06-21 08:50AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue EstimatesZacks
07:30AM	Intellia Therapeutics Announces First Quarter 2021 Financial ResultsGlobeNewswire
May-06-21 06:15AM	Intellia Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Apr-30-21 11:15AM	3 Exciting Biotech Stocks to Buy Right NowMotley Fool
Apr-29-21 05:05AM	Analysts Estimate Intellia Therapeutics, Inc. (NTLA) to Report a Decline in Earnings: What to Look Out forZacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company UpdatesGlobeNewswire
Apr-28-21 05:30AM	Cutting Edge Intellia Therapeutics Charts Are BullishTheStreet.com
Apr-27-21 04:35AM	Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire
Apr-16-21 03:51AM	CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks TodayInvestorPlace
Apr-14-21 12:30PM	Is NTLA Stock A Buy or Sell?Insider Monkey
Apr-12-21 07:30AM	Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of DirectorsGlobeNewswire
Mar-30-21 07:30AM	Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR AmyloidosisGlobeNewswire
Mar-25-21 07:30AM	Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base EditorsGlobeNewswire
Mar-10-21 07:30AM	Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposiumGlobeNewswire
Mar-03-21 01:46AM	The Intellia Therapeutics (NASDAQ:NTLA) Share Price Is Up 360% And Shareholders Are DelightedSimply Wall St.
Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the USInsider Monkey
Feb-26-21 12:59PM	Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4Zacks
Feb-25-21 09:30AM	Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call TranscriptMotley Fool
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial ResultsGlobeNewswire
Feb-25-21 05:45AM	Intellia Therapeutics, Inc. to Host Earnings CallACCESSWIRE
Feb-18-21 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company UpdatesGlobeNewswire
Jan-29-21 09:44AM	A Highly Specialized Gene Editing Stock with a Clear Pathway to Big GainsInvestorPlace
Jan-20-21 08:23AM	The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia TherapeuticsZacks
Jan-15-21 06:12AM	7 CRISPR Stocks for the Future of MedicineInvestorPlace
Jan-14-21 03:11AM	With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBarrons.com
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex PharmaceuticalsZacks
Jan-08-21 09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline UpdateZacks
Jan-07-21 04:24AM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
02:33AM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
Jan-07-21 01:05AM	Why Intellia Therapeutics Stock Is Soaring TodayMotley Fool
08:42AM	3 Biotech Technological Developments to Watch Out For in 2021Zacks
Jan-07-21 07:30AM	Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021GlobeNewswire
Jan-06-21 11:00AM	A New Gene-Editing Technique May Be Able to Help Children Who Prematurely AgeBarrons.com
Jan-04-21 09:27AM	5 Disruptive Biotech Stocks With Solid Long-Term PotentialZacks
Jan-01-21 01:22AM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Could Be 41% Below Their Intrinsic Value EstimateSimply Wall St.
Dec-30-20 10:42AM	The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana TherapeuticsZacks
Dec-29-20 12:27PM	Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayMotley Fool
09:37AM	5 Biotech Stocks That Have Gained More Than 200% in 2020Zacks
Dec-21-20 04:24AM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
12:43PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
Dec-16-20 09:33AM	Is NTLA A Good Stock To Buy Now?Insider Monkey
Dec-12-20 09:00AM	Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT DeficiencyGlobeNewswire

Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

List of SPAC Stocks List of EV Stocks and Related Stocks Top 100 popular stocks on Robinhood List of Marijuana Stocks

Open in Yahoo | Open in Google | Open in Finviz

Intellia Therapeutics (NTLA) Stock Discussions on Social Media